---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-035544"
form_type: "8-K"
ticker: "ATXI"
cik: "0001644963"
company_name: "AVENUE THERAPEUTICS, INC."
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T15:15:11.510108+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Avenue Therapeutics reports FY2023 net loss of $10.5M; AJ201 Phase 1b/2a enrollment complete, topline data Q2 2024

## Summary
- Net loss of $10.5M ($0.98 per share) vs $3.6M loss in FY2022; cash $1.8M as of Dec 31, 2023.
- Completed enrollment in AJ201 Phase 1b/2a for SBMA (25 patients); topline data expected Q2 2024.
- Reached final agreement with FDA on Phase 3 safety study protocol for IV tramadol; aims to initiate pending financing.
- Nasdaq granted extension to May 20, 2024 to meet continued listing requirements.
- Raised $5.0M gross in January 2024 via warrant inducement.

## SEC filing metadata
- accession: 0001104659-24-035544
- form_type: 8-K
- ticker: ATXI
- cik: 0001644963
- company_name: AVENUE THERAPEUTICS, INC.
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/0001104659-24-035544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/tm248747d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-035544
- JSON: https://secwatch.observer/filing/0001104659-24-035544.json
- Plain text: https://secwatch.observer/filing/0001104659-24-035544.txt

## Key facts
- Earnings Releases
  AVENUE THERAPEUTICS, INC. reported the fiscal year ended December 31, 2023 results: net income Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63, EPS $0.98 per share.
  - Period: the fiscal year ended December 31, 2023
  - Net income: Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63
  - EPS: $0.98 per share
  - Result: reported results
  source text: Net loss for the full year 2023 was $10.5 million, or $0.98 per share, compared to a net loss of $3.6 million, or $1.63 per share, in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1644963/000110465924035544/0001104659-24-035544-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.